Sofovir-C 400 mg is an advanced antiviral medication designed for the treatment of chronic hepatitis C (CHC) infection. It is a nucleotide analog NS5B polymerase inhibitor that prevents the hepatitis C virus (HCV) from replicating in the liver. Sofovir-C 400 mg is used as part of combination therapy with other antiviral agents such as Ribavirin or Pegylated Interferon and Ribavirin, depending on the patient’s HCV genotype and clinical condition. Its efficacy has been established in patients with HCV genotypes 1, 2, 3, and 4, including those co-infected with HIV-1 or awaiting liver transplantation due to hepatocellular carcinoma.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Indications

Sofovir-C 400 mg is indicated for:

• Treatment of chronic hepatitis C (CHC) infection in adults

• Patients with HCV genotypes 1, 2, 3, and 4

• HCV/HIV-1 co-infected patients

• Patients with hepatocellular carcinoma awaiting liver transplantation

• Should always be used as part of a combination antiviral regimen

Pharmacology and Mode of Action

Sofovir-C 400 mg works as a nucleotide analog inhibitor, targeting the HCV NS5B RNA-dependent RNA polymerase. After intracellular conversion to the active triphosphate form (GS-461203), it incorporates into the viral RNA chain and acts as a chain terminator, preventing further replication of HCV genetic material. By specifically binding to the NS5B polymerase’s active site, Sofovir-C effectively blocks viral replication, leading to a significant reduction in viral load.

Dosage and Administration

• Standard dose: 1 tablet (400 mg) once daily, with or without food

• Combination therapy regimens:

  • Genotype 1 or 4: Sofovir-C 400 mg + Peginterferon alfa + Ribavirin for 12 weeks

  • Genotype 2: Sofovir-C 400 mg + Ribavirin for 12 weeks

  • Genotype 3: Sofovir-C 400 mg + Ribavirin for 24 weeks

  • HCV patients ineligible for Interferon: Sofovir-C + Ribavirin for 24 weeks

  • Patients awaiting liver transplantation: Sofovir-C + Ribavirin for up to 48 weeks or until transplantation

• Pediatric use: Not established for children under 18 years

• Geriatric use: Standard adult dose is suitable; no adjustment required based on age

Drug Interactions

• Avoid co-administration with potent P-gp inducers (rifampicin, St. John’s wort, carbamazepine, phenytoin)

• Amiodarone with Sofovir-C and another direct-acting antiviral may cause serious bradycardia

• Monitor use with BCRP or P-gp inhibitors and beta blockers

Contraindications

• Hypersensitivity to Sofovir-C or any component

• Combination therapy with Ribavirin or Peginterferon/Ribavirin in pregnant women or men with pregnant partners due to risk of birth defects

  রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Side Effects

Sofovir-C 400 mg is generally well tolerated. Common side effects include:

• Fatigue and headache

• Nausea, insomnia, and anemia (when used with Peginterferon/Ribavirin)

• Pruritus, rash, myalgia, and mild gastrointestinal disturbances

• Rarely, serious cardiac events in combination with amiodarone

Precautions and Warnings

• Co-administration with amiodarone and another DAA is not recommended

• Monitor for bradycardia in high-risk patients

• Ensure effective contraception during combination therapy with Ribavirin

Pregnancy and Lactation

• Pregnancy Category B: Insufficient well-controlled studies; use only if clearly necessary

• Nursing mothers: Unknown if Sofovir-C is excreted in breast milk; weigh potential risks versus benefits

Storage Conditions

• Store in a cool, dry place, protected from light

• Keep out of reach of children.